RB 101 是一种可穿透血脑屏障的氨基肽酶 N 和中性内肽酶-24.11 双重抑制剂,也是一种前药,可阻断脑啡肽的降解、提高细胞外脑啡肽水平并激活 δ 阿片受体和多巴胺 D1 受体,可用于疼痛、抑郁综合征和糖尿病神经病变的相关研究。
产品编号: MS-C68791 CAS No.: 135949-60-9 分子式: C31H38N2O3S3 分子量: 582.84
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

RB 101 是一种可穿透血脑屏障的氨基肽酶 N 和中性内肽酶-24.11 双重抑制剂,也是一种前药,可阻断脑啡肽的降解、提高细胞外脑啡肽水平并激活 δ 阿片受体和多巴胺 D1 受体,可用于疼痛、抑郁综合征和糖尿病神经病变的相关研究。

生物实验数据

生物活性 RB 101 is a blood-brain barrier-penetrant dual inhibitor of aminopeptidase N and neutral endopeptidase-24.11, and also a prodrug, which blocks enkephalin degradation, elevates extracellular enkephalin levels, and activates δ opioid receptors and dopamine D1 receptors, and can be used in research related to pain, depressive syndromes, and diabetic neuropathy.
IC50 & Target

δ Opioid Receptor/DOR

 

D1 Receptor

 

体外研究
(In Vitro)

RB 101 可通过抑制脑啡肽降解酶,增强大鼠脊髓组织中甲硫氨酸脑啡肽样物质的自发性释放。

体内研究
(In Vivo)

RB 101 (2.5-40 mg/kg;静脉注射;单次给药) 可在基础条件下剂量依赖性地抑制 [3H] 二丙诺啡与小鼠脑内阿片受体的结合。
RB 101 (5-20 mg/kg;静脉注射;单次给药) 可增强小鼠的应激诱导镇痛效应,当与温水游泳应激联合作用时,5 mg/kg 剂量下的镇痛率可达 85%。
RB 101 (1.25-10 mg/kg;静脉注射;单次缓慢注射) 可通过 δ 阿片受体和多巴胺 D1 受体的激活,在小鼠中诱导剂量依赖性的持久自发性运动活动增强。
RB 101 (2.5-10 mg/kg;静脉注射;单次缓慢注射) 可通过激动 δ 阿片受体和多巴胺 D1 受体,呈剂量依赖性地减弱受电击小鼠的运动条件性抑制,并增加纹状体多巴胺周转率。
RB 101 (2.5-10 mg/kg;静脉注射;单次缓慢推注) 可通过激活 δ 阿片受体和多巴胺 D1 受体显著缩短小鼠强迫游泳实验中的不动时间。
RB 101 (5-40 mg/kg;静脉注射) 可在 Streptozocin (MS-Q80520) 诱导的神经性疼痛糖尿病大鼠中产生剂量依赖性、由 μ-和 δ-阿片受体介导的镇痛作用,在 20 和 40 mg/kg 静脉注射剂量下可完全抑制机械性痛觉过敏。

Animal Model: Male albino mice (Depre, France; 20-22 g)
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.v.; single administration
Result: Induced a dose-dependent reduction in [3H]diprenorphine binding: 5 mg/kg caused 20% displacement, 10 mg/kg caused 30% displacement (plateau effect), with no additional displacement at 20 mg/kg.
Induced a non-significant increase in jump latency at 5 mg/kg.
Produced statistically significant analgesia relative to controls at 10 mg/kg, 20 mg/kg, and 40 mg/kg, with analgesia percentages increasing with dose.
Animal Model: Male albino mice (Depre, France; 20-22 g; forced warm-water swim stress model)
Dosage: 5 mg/kg; 20 mg/kg
Administration: i.v.; single administration
Result: Combined with stress induced 85% analgesia at 5 mg/kg (vs. 48% analgesia from stress alone), and this combined analgesia was blocked by naloxone but not by naltrindole.
Combined with stress caused 45% displacement of [3H]diprenorphine relative to unstressed controls at 5 mg/kg, while 20 mg/kg combined with stress caused 43% displacement relative to unstressed controls.
Animal Model: Swiss albino mice (male, 20-22 g for spontaneous motor activity and forced swim tests; ~30 g, 8 weeks old for conditioned suppression of motility test)
Dosage: 1.25 mg/kg; 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v.; single slow injection
Result: Induced a dose-dependent increase in locomotor activity, with effects peaking between 5-10 min post-injection.
Remained significant at 15 and 20 min post-injection at 10 mg/kg.
Produced a significant cumulative increase in motor activity (linear locomotion + rears) over 10 and 20 min at 5 mg/kg, which was antagonized by pre-treatment with naltrindole (0.1 mg/kg s.c.) and SCH 23390 (0.07 mg/kg s.c.), but not sulpiride (25 mg/kg i.p.).
Animal Model: Swiss albino mice (male, ~30 g, 8 weeks old)
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v.; single slow injection
Result: Did not alter locomotor activity at 2.5 and 5 mg/kg, but increased activity at 10 mg/kg in non-shocked mice.
Dose-dependently reduced conditioned motility suppression at 5 and 10 mg/kg in shocked mice.
Effect of 5 mg/kg was antagonized by pre-treatment with naltrindole (0.1 mg/kg s.c.) and SCH 23390 (0.07 mg/kg s.c.), but not sulpiride (25 mg/kg i.p.).
Significantly increased striatal DOPAC/DA and HVA/DA ratios to 0.108 and 0.100, respectively, in shocked mice treated with 5 mg/kg, an effect blocked by naltrindole.
Animal Model: Swiss albino mice (male, 20-22 g)
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v.; single slow injection
Result: Significantly shortened the duration of immobility in the forced swim test at 5 and 10 mg/kg.
Effect of 5 mg/kg was antagonized by pre-treatment with naltrindole (0.1 mg/kg s.c.) and SCH 23390 (0.07 mg/kg s.c.), but not sulpiride (25 mg/kg i.p.).
Animal Model: Sprague-Dawley (male, 300 g, Streptozocin-induced neuropathic pain)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.v.
Result: Produced a dose-dependent antinociceptive effect on mechanical hyperalgesia, with 20 and 40 mg/kg doses completely suppressing diabetes-induced hyperalgesia (P<0.001).
Achieved a maximal vocalization threshold elevation of +294 g (+178% of predrug score) at 20 minutes with 40 mg/kg dose, which was not significantly different from the maximal effect of 20 mg/kg.
Had a short duration of action (20 minutes) with 5 mg/kg dose, while 10, 20, and 40 mg/kg doses lasted 60 minutes.
Showed a ceiling effect at 40 mg/kg confirmed by AUC values.
Produced a significant increase in withdrawal threshold for mechanical allodynia only with 40 mg/kg dose, with a maximal increase of +8.3 g at 20 minutes (P<0.01), lasting 20 minutes.
Did not significantly affect tail immersion reaction time for thermal allodynia at any dose.
Had its antinociceptive effect at 20 mg/kg completely abolished by pretreatment with 0.5 mg/kg i.v. naloxone or 1 μg/rat i.t. naltrindole.

化学信息

分子量 582.84
分子式 C31H38N2O3S3
CAS No. 135949-60-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础